These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 7725239)

  • 1. 6 beta-[125iodo]-3, 14-dihydroxy-17-methyl-4, 5 alpha-epoxymorphinan ([125I]IOXY-AGO): a potent and selective radioligand for opioid mu receptors.
    Xu H; Goodman CB; Partilla JS; Ni Q; Kayakiri H; Rice KC; Rothman RB
    Synapse; 1995 Feb; 19(2):105-11. PubMed ID: 7725239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor.
    Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB
    Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the kappa 2 receptor in guinea pig brain.
    Ni Q; Xu H; Partilla JS; de Costa BR; Rice KC; Kayakiri H; Rothman RB
    Peptides; 1995; 16(6):1083-95. PubMed ID: 8532593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand selectivity of cloned human and rat opioid mu receptors.
    Rothman RB; Xu H; Wang JB; Partilla JS; Kayakiri H; Rice KC; Uhl GR
    Synapse; 1995 Sep; 21(1):60-4. PubMed ID: 8525463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective labeling of kappa 2 opioid receptors in rat brain by [125I]IOXY: interaction of opioid peptides and other drugs with multiple kappa 2a binding sites.
    Ni Q; Xu H; Partilla JS; de Costa BR; Rice KC; Rothman RB
    Peptides; 1993; 14(6):1279-93. PubMed ID: 8134311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
    Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
    J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
    Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
    Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
    Knapp RJ; Santoro G; De Leon IA; Lee KB; Edsall SA; Waite S; Malatynska E; Varga E; Calderon SN; Rice KC; Rothman RB; Porreca F; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1284-91. PubMed ID: 8667189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands.
    Calderon SN; Rice KC; Rothman RB; Porreca F; Flippen-Anderson JL; Kayakiri H; Xu H; Becketts K; Smith LE; Bilsky EJ; Davis P; Horvath R
    J Med Chem; 1997 Feb; 40(5):695-704. PubMed ID: 9057856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization.
    Bradford CS; Walthers EA; Stanley DJ; Baugh MM; Moore FL
    Gen Comp Endocrinol; 2006 May; 146(3):275-90. PubMed ID: 16375901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan.
    de Costa BR; Iadarola MJ; Rothman RB; Berman KF; George C; Newman AH; Mahboubi A; Jacobson AE; Rice KC
    J Med Chem; 1992 Jul; 35(15):2826-35. PubMed ID: 1322988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphin A(1-8): stability and implications for in vitro opioid activity.
    Bell KM; Traynor JR
    Can J Physiol Pharmacol; 1998 Mar; 76(3):325-33. PubMed ID: 9673796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
    Hjorth SA; Thirstrup K; Schwartz TW
    Mol Pharmacol; 1996 Oct; 50(4):977-84. PubMed ID: 8863844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.